Please assess the completion status of the following clinical trial:

Trial Title: Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* An adult, age 18 and above~* Diagnosed with Crohn's disease AT LEAST six (6) months prior to screening~* Crohn's disease diagnosis was verified by one of these procedures: 1) Colonoscopy 2) Capsule endoscopy 3) Computed Tomography (CT) scan 4) Magnetic Resonance Imaging (MRI) 5) Ultrasound~* Active Crohn's disease at the time of screening~* Female participants: Agree to practice two effective methods of contraception, at the same time, from the time of signing the informed consent form, during the entire study treatment and for two (2) months after taking the last dose of study treatment.~* Male participants: Agree to practice effective barrier contraception during the entire study treatment period and for two (2) months after taking the last dose of study treatment.~Exclusion Criteria:~* Currently pregnant or breastfeeding~* Have known or suspected hypersensitivity to any component of the product~* Had more than three (3) small bowel resections or diagnosis of short bowel syndrome~* Currently anticipate undergoing any major surgical intervention for Crohn's disease during the next six (6) months~* Previously been treated with any Qu Biologics' Site Specific Immunomodulators (SSIs) for any disease~* Diagnosed with chronic (i.e., long term) hepatitis B or C infection~* Diagnosed with congenital (i.e., existing at or before birth) or acquired immunodeficiency (i.e., lack of body defense system). For example, human immunodeficiency virus (HIV) infection, organ transplantation (i.e., specifically received an organ from a donor), etc.~* Daily use of narcotic drugs containing opiates (such as morphine, codeine, etc.) for pain control~* Have a current or recent history (within the past 12 months) of alcohol dependence or illicit drug use, with the exception of medicinal marijuana prescribed by a physician~* Have a history of cancer within the last five (5) years. Exceptions may apply for cervical cancer and some forms of skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QBECO (Type: EXPERIMENTAL): Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).